This article is more than 5 years old. Information may no longer be current.
New drug trial results from EASD
Endocrine Today has compiled a list of breaking drug trial news reports posted from the annual meeting of the European Association for the Study of Diabetes Annual Meeting.
Healio.com/Endocrinology readers were interested in how semaglutide measures up against other diabetes medications, the complicated findings of the CONCLUDE trial, the cardiovascular protective benefits of dapagliflozin and more.
All content from the meeting is available under the Meeting News tab.
SUSTAIN 8: Semaglutide bests canagliflozin in head-to-head type 2 diabetes trial
Adults with type 2 diabetes randomly assigned to the GLP-1 receptor agonist semaglutide experienced a greater reduction in HbA1c and lost more weight than those assigned to the SGLT2 inhibitor canagliflozin in a head-to-head trial of the two drug classes.
CONCLUDE: ‘Uncertainties’ complicate hypoglycemia findings comparing insulin degludec vs. glargine
Adults with insulin-dependent type 2 diabetes assigned to insulin degludec for up to 88 weeks experienced fewer severe or confirmed symptomatic hypoglycemia episodes during a maintenance phase when compared with similar adults assigned to insulin glargine 300 u/mL; however, researchers cautioned that several factors complicate the data, according to analyses from the CONCLUDE trial.
DAPA-HF: SGLT2 inhibitor reduces heart failure risk even for patients without diabetes
The diabetes medication dapagliflozin was shown to reduce the risks for worsening heart failure and cardiovascular death among adults with heart failure with reduced ejection fracture regardless of diabetes status, according to findings from the DAPA-HF trial.
SUSTAIN 10: Semaglutide tops liraglutide providing support for changing prescribing patterns
Among a cohort of adults with type 2 diabetes already using oral medications, those assigned to add a weekly injection of 1 mg semaglutide vs. 1.2 mg liraglutide experienced larger decreases in HbA1c and body weight, according to findings from the SUSTAIN 10 trial.
VERIFY: Early addition of vildagliptin outperforms metformin alone, later add-on
Among a cohort of adults with recent type 2 diabetes prescribed metformin, those assigned to receive vildagliptin as an add-on therapy maintained better long-term glycemic control than those who continued on monotherapy, according to findings from the VERIFY trial.